(Date:5/16/2008)...mpaign to Emphasize the Importance of Oral and Ove... -- National dental insurer United,Concordia Denta...tion,between Oral Health America and the British D...of oral health to overall health. Beginning May 18...tes for the first time,making it the largest inde...
(Date:5/16/2008)...m an international, multicenter Phase III clinical...erapy everolimus (RAD001) significantly delays can... cancer whose disease had worsened on other treatm...attending physician at Memorial Sloan-Kettering Ca... on May 31 at the annual meeting of the American S...
(Date:5/16/2008)...ds located just beneath the lining of the uterus (...rial cavity after uterine artery embolization (UAE...rding to a new study. , The study included 49 p...mination before and after UAE. The study found tha...ted to the endometrial cavity after UAE, said Sach...
(Date:5/16/2008)... Fundraiser Seeks to Raise $38 Million for Life-th...ire-USNewswire/ -- Walkers in nearly,every state w...- May 17 and,18 -- by participating in GREAT STRID...c Fibrosis Foundation announced today., May is Na...rosis is a,life-threatening genetic disease that c...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Drug fends off kidney cancer progression 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patien...rld,s most common cancers, can expect,further trea...erceptin(R),(trastuzumab) following new data that ... Clinical Oncology (ASCO) annual meeting in Chicag... will attend the meeting which,is the premier even...
(Date:5/15/2008)...- First in human clinical data highlight safety pr...advanced solid tumors -, BRISBANE, Calif., May 15... held biopharmaceutical company developing novel c...ing its lead PARP inhibitor, BSI-201, will,be pres...ology annual,meeting in Chicago., Findings will b...
(Date:5/15/2008)...hase II Data Presented at ASCO Showed Acceptable T...e of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N....motherapeutic agent eribulin mesylate (E7389) demo...on of women with locally advanced or metastatic,br...r Phase II clinical,trial. The study also suggests...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Genes and environment interact in first graders to predict physical but not social aggression 2145 1Genes and environment interact in first graders to predict physical but not social aggression 2145 2The Ensign Group Inc Announces the Appointment of Covey C Christensen as President of Its Flagstone Subsidiary 11233 1The Ensign Group Inc Announces the Appointment of Covey C Christensen as President of Its Flagstone Subsidiary 11233 2New funding to charge energy research at UCL and the London Centre for Nanotechnology 3094 1New funding to charge energy research at UCL and the London Centre for Nanotechnology 3094 2Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 1Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 2Celebrity Cook Paula Deen and Husband Michael Groover Bring Smithfield Foods Helping Hungry Homes 28TM 29 Tour to L A 11232 3...EM, & LUND, Sweden--(BUSINESS WIRE)--May 1, 20...e Biotech AB today,announced that data from a 36-w...Phase IIb study demonstrated that an oral 0.6 mg,d...d magnetic,resonance imaging (MRI) disease activit...rated. In addition, there was a favorable,trend to...
... confirmed EDSS progression reduced by 40 percent ...7 /PRNewswire/ -- Bayer HealthCare,Pharmaceuticals...te,initiation(1) of Betaseron(R) (interferon beta-...stive of multiple sclerosis (MS),can significantly...ent as measured by the Expanded Disability Status ...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: